Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240551 | 0.90 | SCD (0.47) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL12172142 | 0.86 | SCD (0.47) | SCDPKMCOMT | |
| SCHEMBL1911665 | 0.85 | SCD (0.47) | SCDPOLBKDM4ECOMTALDH1A1 | |
| SCHEMBL10272408 | 0.85 | SCD (0.50) | SCDHDAC1 | |
| SCHEMBL347629 | 0.85 | SCD (0.60) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL1909775 | 0.84 | SCD (0.46) | SCDRAB9AMAPTALDH1A1 | |
| SCHEMBL348021 | 0.83 | SCD (0.45) | SCDPOLBKDM4ELMNA | |
| SCHEMBL347089 | 0.80 | SCD (0.59) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL4196509 | 0.80 | COMT (0.39) | SCDRAB9APOLBKDM4EMAPT | |
| SCHEMBL348517 | 0.80 | SCD (0.47) | SCDCOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | claimed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885RAB9A 3869/4885POLB 2057/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885RAB9A 4305/4885POLB 2337/4885 |
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885RAB9A 4305/4885POLB 2337/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | SCD 1/4885RAB9A 4305/4885POLB 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.